This post is also available in:
עברית (Hebrew)
Regeneron Pharmaceuticals has announced plans to acquire the genetic testing company 23andMe for $256 million, with a clear focus on leveraging its vast DNA database for drug research and development. The U.S.-based biotech giant disclosed on Monday that it intends to continue 23andMe’s consumer genomics services without interruption, while integrating its genetic data into its own research efforts.
This strategic move comes on the heels of a bankruptcy auction held last week, where Regeneron emerged as the winning bidder. The acquisition grants Regeneron access to one of the largest repositories of consumer genetic data, collected over years through 23andMe’s popular at-home DNA testing kits.
Central to Regeneron’s plan is the use of de-identified genetic information for drug discovery, a field in which it has extensive experience. According to the company’s statement, since 2013, the company’s Genetics Center has sequenced genetic data from nearly three million individuals, linking anonymized DNA profiles with medical records to accelerate the development of new treatments.
In light of recent data security concerns, including a 2023 breach that exposed the genetic data of approximately seven million users, Regeneron has emphasized its commitment to maintaining the strictest standards of data privacy and ethical oversight. Company representatives confirmed that all data handling will comply with 23andMe’s existing privacy policies, U.S. laws, and guidance from regulatory bodies.
An independent Customer Privacy Ombudsman will review Regeneron’s proposed data usage policies, and further details are expected at a final court hearing scheduled for June 14.
While the acquisition is positioned as a step forward in precision medicine, it also raises questions about consumer consent and data governance. Regeneron has not yet clarified whether users will be able to opt out of future research initiatives.
The transaction is expected to be finalized in the third quarter of 2025.
